ATE389666T1 - Hohe expressionsrate von proteinen - Google Patents

Hohe expressionsrate von proteinen

Info

Publication number
ATE389666T1
ATE389666T1 AT97941703T AT97941703T ATE389666T1 AT E389666 T1 ATE389666 T1 AT E389666T1 AT 97941703 T AT97941703 T AT 97941703T AT 97941703 T AT97941703 T AT 97941703T AT E389666 T1 ATE389666 T1 AT E389666T1
Authority
AT
Austria
Prior art keywords
proteins
high expression
expression rate
gene encoding
protein
Prior art date
Application number
AT97941703T
Other languages
English (en)
Inventor
Brian Seed
Juergen Haas
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24881447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE389666(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE389666T1 publication Critical patent/ATE389666T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT97941703T 1996-09-20 1997-09-18 Hohe expressionsrate von proteinen ATE389666T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08717294 US6114148C1 (en) 1996-09-20 1996-09-20 High level expression of proteins

Publications (1)

Publication Number Publication Date
ATE389666T1 true ATE389666T1 (de) 2008-04-15

Family

ID=24881447

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941703T ATE389666T1 (de) 1996-09-20 1997-09-18 Hohe expressionsrate von proteinen

Country Status (19)

Country Link
US (1) US6114148C1 (de)
EP (1) EP0929564B1 (de)
JP (1) JP2001503252A (de)
KR (1) KR100490321B1 (de)
CN (1) CN1307195C (de)
AT (1) ATE389666T1 (de)
AU (1) AU737122B2 (de)
BR (1) BR9712077A (de)
CA (1) CA2265976C (de)
CZ (1) CZ96899A3 (de)
DE (1) DE69738586T2 (de)
DK (1) DK0929564T3 (de)
ES (1) ES2304791T3 (de)
HU (1) HUP9904239A3 (de)
MX (1) MX259447B (de)
PL (2) PL191300B1 (de)
RU (1) RU2233329C2 (de)
TR (1) TR199900624T2 (de)
WO (1) WO1998012207A1 (de)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
EP0969862B1 (de) * 1997-02-07 2006-10-18 Merck & Co., Inc. Synthetische hiv gag gene
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
EP1002091B1 (de) * 1997-07-09 2012-02-29 Coridon Pty Limited Nukleinsäuresequenz und verfahren zur selektiven expression eines proteins in einer zielzelle oder -gewebe
AUPP807899A0 (en) * 1999-01-08 1999-02-04 University Of Queensland, The Codon utilization
US6602677B1 (en) * 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
CN1325646C (zh) * 1997-10-20 2007-07-11 Gtc生物治疗学公司 修饰的核酸序列以及增加细胞系统中mRNA水平和蛋白质表达的方法
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9810752D0 (en) * 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US6958226B1 (en) 1998-09-11 2005-10-25 The Children's Medical Center Corp. Packaging cells comprising codon-optimized gagpol sequences and lacking lentiviral accessory proteins
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
US20090017533A1 (en) * 1998-09-29 2009-01-15 Shire Human Genetic Therapies, Inc., A Delaware Corporation Optimized messenger rna
US20050037335A1 (en) * 1998-11-07 2005-02-17 Wolfgang Hillen Method for identifying novel transcriptional regulatory proteins
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AUPP807799A0 (en) * 1999-01-08 1999-02-04 University Of Queensland, The Polynucleotide and method
CA2369119A1 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
WO2000065076A2 (en) * 1999-04-26 2000-11-02 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes
US20050271689A1 (en) * 2003-07-11 2005-12-08 Chun-Ming Huang Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
WO2000075347A2 (en) * 1999-06-07 2000-12-14 Wolfgang Hillen Tet repressor-based transcriptional regulatory proteins
WO2002064799A2 (en) * 1999-09-28 2002-08-22 Transkaryotic Therapies, Inc. Optimized messenger rna
EP2275559A3 (de) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimierte Boten-RNA (mRNA)
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
US20040063653A1 (en) * 2000-12-21 2004-04-01 Shiver John W. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
KR20010102331A (ko) * 1999-12-24 2001-11-15 요트.게.아. 롤페즈 인장 마스크를 포함하는 컬러 음극선관
US6502774B1 (en) * 2000-03-08 2003-01-07 J + L Fiber Services, Inc. Refiner disk sensor and sensor refiner disk
DK1266006T3 (da) * 2000-03-22 2006-01-16 Octagene Gmbh Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
EP1136553A1 (de) * 2000-03-22 2001-09-26 Octagene GmbH Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US20030157643A1 (en) * 2000-08-24 2003-08-21 Almond Brian D Synthetic nucleic acids from aquatic species
US7879540B1 (en) * 2000-08-24 2011-02-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
EP2842964A1 (de) 2001-06-05 2015-03-04 Curevac GmbH Virtuelles Verfahren zur Ermittlung einer modifzierten mRNA-Sequenz
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003020876A2 (en) * 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US6911538B2 (en) * 2002-01-16 2005-06-28 Washington University Engineered open reading frame for p53
AU2003228809A1 (en) 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
AU2003249208B2 (en) * 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
JP4528623B2 (ja) * 2002-09-16 2010-08-18 プロメガ コーポレイション 迅速分解性レポーター融合タンパク質
WO2004042059A1 (en) * 2002-11-08 2004-05-21 The University Of Queensland A method for optimising gene expression using synonymous codon optimisation
CA2525825A1 (en) * 2003-05-15 2005-01-27 Chiron Corporation Hiv polynucleotides and polypeptides derived from botswana mj4
GB0325379D0 (en) * 2003-10-30 2003-12-03 Oxford Biomedica Ltd Vectors
US9410170B2 (en) * 2003-11-20 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods of in vitro protein synthesis
US20050112551A1 (en) * 2003-11-24 2005-05-26 Agouron Pharmaceuticals, Inc. Dual assay for evaluating activity and cytotoxicity of compounds in the same population of cells
EP1751298A4 (de) 2004-05-18 2009-11-11 Intrexon Corp Verfahren zum dynamischen vektorzusammenbau von dna-klonierungsvektorplasmiden
US20080044853A1 (en) 2004-06-21 2008-02-21 Novozymes A/S Stably Maintained Multiple Copies of at Least Two Orf in the Same Orientation
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
EP1773874B1 (de) * 2004-08-04 2012-10-24 Allergan, Inc. Optimierung der expression von aktivem botulinumtoxin a
US7728118B2 (en) * 2004-09-17 2010-06-01 Promega Corporation Synthetic nucleic acid molecule compositions and methods of preparation
US20060194214A1 (en) * 2005-02-28 2006-08-31 George Church Methods for assembly of high fidelity synthetic polynucleotides
CA2584984A1 (en) * 2004-10-18 2006-04-27 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
US20070122817A1 (en) * 2005-02-28 2007-05-31 George Church Methods for assembly of high fidelity synthetic polynucleotides
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
JP5361386B2 (ja) * 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ マトリックスメタロプロテイナーゼ１１ワクチン
CN101287832A (zh) * 2005-10-14 2008-10-15 艾尼纳制药公司 Gpr22和其相关方法
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
CN101998965B (zh) 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US8126653B2 (en) * 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
JP6073247B2 (ja) 2011-01-17 2017-02-01 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 植物で核酸を発現させるベクター
SG192022A1 (en) 2011-01-17 2013-08-30 Philip Morris Prod Protein expression in plants
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP2721153B1 (de) 2011-06-16 2019-08-28 The Regents of The University of California Synthetische gencluster
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US20130109596A1 (en) 2011-09-26 2013-05-02 Life Technologies Corporation High efficiency, small volume nucleic acid synthesis
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014063155A1 (en) * 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
PL2958943T3 (pl) 2013-02-20 2020-04-30 The Trustees Of The University Of Pennsylvania Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
EP3071974A2 (de) 2013-11-19 2016-09-28 Prothena Biosciences Limited Überwachung der immuntherapie von lewy-körperchen-krankheit aus verstopfungssymptomen
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
JP6728053B2 (ja) 2014-03-12 2020-07-22 プロセナ バイオサイエンシーズ リミテッド 抗ｍｃａｍ抗体及び関連する使用方法
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
EP3193915A1 (de) 2014-07-21 2017-07-26 Novartis AG Kombinationen aus niedrigen, immunfördernden dosen von mtor-inhibitoren und cars
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
AU2015301598B2 (en) 2014-08-13 2020-07-16 Liron Elkouby An improved expression cassette for packaging and expression of variant Factor VIII for the treatment of hemostasis disorders
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP4183806A3 (de) 2014-11-12 2023-08-02 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
CN115927293A (zh) 2014-12-09 2023-04-07 生命技术公司 高效小体积核酸合成
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
EP3280795B1 (de) 2015-04-07 2021-03-24 Novartis AG Kombination von chimärer antigen rezeptor therapie und amino pyrimidin derivaten
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
WO2016168595A1 (en) 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016170176A1 (en) 2015-04-22 2016-10-27 Curevac Ag Rna containing composition for treatment of tumor diseases
EP3286211A1 (de) 2015-04-23 2018-02-28 Novartis AG Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker
EP3294885B1 (de) 2015-05-08 2020-07-01 CureVac Real Estate GmbH Verfahren zur herstellung von rna
WO2016193206A1 (en) 2015-05-29 2016-12-08 Curevac Ag A method for producing and purifying rna, comprising at least one step of tangential flow filtration
KR102594707B1 (ko) 2015-07-13 2023-10-26 피벗 바이오, 인크. 식물 형질 개선을 위한 방법 및 조성물
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
JP2018537119A (ja) 2015-10-05 2018-12-20 マサチューセッツ インスティテュート オブ テクノロジー リファクターされたｎｉｆクラスターを使用する窒素固定
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3374388A1 (de) 2015-11-13 2018-09-19 Baxalta Incorporated Virale vektoren zur codierung von rekombinanten fviii-varianten mit erhöhter expression zur gentherapie von hämophilie a
SG11201804070XA (en) 2015-11-13 2018-06-28 Baxalta Inc Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
CN108603200B (zh) 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
AU2016380262B2 (en) 2015-12-28 2023-02-09 Novartis Ag Methods of making chimeric antigen receptor -expressing cells
CN109072195A (zh) 2015-12-30 2018-12-21 诺华股份有限公司 具有增强功效的免疫效应细胞疗法
EP3851457A1 (de) 2016-01-21 2021-07-21 Novartis AG Gegen cll-1 gerichtete multispezifische moleküle
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
KR20250011248A (ko) 2016-03-11 2025-01-21 스칼러 락, 인크. TGFβ1-결합 이뮤노글로불린 및 그의 용도
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CN109715808A (zh) 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
DK3452507T3 (da) 2016-05-02 2022-11-14 Prothena Biosciences Ltd Tau-immunoterapi
CU24538B1 (es) 2016-05-02 2021-08-06 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
CN114689870B (zh) * 2016-06-02 2025-02-18 朋友股份有限公司 蛋变态反应的抗原
EP3464375A2 (de) 2016-06-02 2019-04-10 Novartis AG Therapeutische schemata für chimäre antigenrezeptor(car)-exprimierende zellen
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478715A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478716A2 (de) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin-antikörper
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN110267677A (zh) 2016-08-01 2019-09-20 诺华股份有限公司 使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
BR112019013908A2 (pt) 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
EP3574005B1 (de) 2017-01-26 2021-12-15 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
US20200048359A1 (en) 2017-02-28 2020-02-13 Novartis Ag Shp inhibitor compositions and uses for chimeric antigen receptor therapy
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112019022906A2 (pt) 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
KR102386890B1 (ko) 2017-05-22 2022-04-15 다케다 야쿠힌 고교 가부시키가이샤 B형 혈우병 유전자 요법을 위한 증가된 발현을 가지는 재조합 fix 변이체를 암호화하는 바이러스 벡터
EP3652535A1 (de) 2017-07-10 2020-05-20 Dana-Farber Cancer Institute, Inc. Identifizierung und verwendung von zytotoxischen t-lymphozyten(ctl)-antigenspezifischen zielzellabtötungsverstärkungsmitteln
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
TWI820034B (zh) 2017-07-31 2023-11-01 香港商映像生物有限公司 眼部疾病之細胞模式及用於眼部疾病的療法
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
WO2019071206A1 (en) 2017-10-06 2019-04-11 Prothena Biosciences Limited METHODS OF DETECTING TRANSTHYRETIN
RU2020116579A (ru) 2017-10-25 2021-11-25 Новартис Аг Способы получения клеток, экспрессирующих химерный антигенный рецептор
MX2020004343A (es) 2017-10-25 2021-01-08 Pivot Bio Inc Métodos y composiciones para mejorar microbios modificados que fijan nitrógeno.
WO2019084342A1 (en) 2017-10-25 2019-05-02 Pivot Bio, Inc. GENETIC TARGETS FOR TARGETING NITROGEN FIXATION FOR IMPROVING PLANT CHARACTERISTICS
US20210179709A1 (en) 2017-10-31 2021-06-17 Novartis Ag Anti-car compositions and methods
MX2020005433A (es) 2017-11-29 2020-08-27 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
US20210189367A1 (en) 2017-12-11 2021-06-24 Senti Biosciences, Inc. Inducible Cell Receptors for Cell-Based Therapeutics
US20210163922A1 (en) 2018-03-19 2021-06-03 Modernatx, Inc. Assembly and error reduction of synthetic genes from oligonucleotides
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (de) 2018-05-01 2021-03-10 Novartis Ag Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses
EP3801769A1 (de) 2018-05-25 2021-04-14 Novartis AG Kombinationstherapie mit therapien mit chimärem antigen-rezeptor (car)
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
CA3103977A1 (en) 2018-06-27 2020-01-02 Pivot Bio, Inc. Agricultural compositions comprising remodeled nitrogen fixing microbes
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AU2019302679A1 (en) 2018-07-11 2021-02-11 Scholar Rock, Inc. High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof
LT3677278T (lt) 2018-07-11 2022-01-10 Scholar Rock, Inc. Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
EP3820279A4 (de) 2018-07-11 2022-04-13 Pivot Bio, Inc. Zeitlich und räumlich zielgerichtete dynamische stickstoffzufuhr durch umgebildete mikroben
AU2019306194A1 (en) 2018-07-16 2021-02-04 Baxalta GmbH Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression
EP3844267B1 (de) 2018-08-31 2025-06-25 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
EP3844265A2 (de) 2018-08-31 2021-07-07 Novartis AG Verfahren zur herstellung von zellen zur expression des chimären antigenrezeptors
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
MX2021004598A (es) 2018-10-23 2021-06-15 Scholar Rock Inc Inhibidores selectivos de rgmc y el uso de los mismos.
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
AU2019386976B2 (en) 2018-11-26 2024-05-30 Forty Seven, LLC Humanized antibodies against c-Kit
MX2021007392A (es) 2018-12-20 2021-08-24 Novartis Ag Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
EP3906415A1 (de) 2019-01-03 2021-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen zur verbesserung der cd8+-t-zellabhängigen immunantworten bei personen mit krebs
BR112021013270A2 (pt) 2019-01-07 2021-11-23 Pivot Bio Inc Ensaios de colonização de plantas utilizando códigos de barras microbianos naturais
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
TW202043267A (zh) 2019-01-30 2020-12-01 美商供石公司 TGFβ之LTBP複合物專一性抑制劑及其用途
BR112021015783A2 (pt) 2019-02-15 2021-10-05 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
WO2020165834A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP3930763A1 (de) 2019-02-25 2022-01-05 Novartis AG Zusammensetzungen mit mesoporösen siliciumdioxidteilchen zur viralen verabreichung
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
WO2020190363A1 (en) 2019-03-19 2020-09-24 Massachusetts Institute Of Technology Control of nitrogen fixation in rhizobia that associate with cereals
US20220168389A1 (en) 2019-04-12 2022-06-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
EP3769816A1 (de) 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123-vektor und verwendungen davon
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
AU2021205433A1 (en) 2020-01-11 2022-08-18 Scholar Rock, Inc. Tgfß inhibitors and use thereof
US20230050148A1 (en) 2020-01-11 2023-02-16 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4104187A1 (de) 2020-02-14 2022-12-21 Novartis AG Verfahren zur vorhersage des ansprechens auf eine chimäre antigen-rezeptor-therapie
KR20220146530A (ko) 2020-02-27 2022-11-01 노파르티스 아게 키메라 항원 수용체-발현 세포의 제조 방법
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
CA3172637A1 (en) 2020-05-01 2021-11-04 Pivot Bio, Inc. Measurement of nitrogen fixation and incorporation
BR112022021933A2 (pt) 2020-05-01 2022-12-13 Pivot Bio Inc Composição agrícola líquida, tecido vegetal agrícola, e, métodos para aplicar uma bactéria diazotrófica, manter uma população de uma bactéria, aumentar a produtividade da cultura vegetal agrícola, fornecer nitrogênio atmosférico, aumentar a produtividade do milho por acre, reduzir a variabilidade no campo da produtividade e melhorar a estabilidade de uma composição agrícola líquida
WO2021248061A1 (en) 2020-06-04 2021-12-09 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7753264B2 (ja) 2020-06-24 2025-10-14 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体
EP4182025A1 (de) 2020-07-16 2023-05-24 Novartis AG Anti-betacellulin-antikörper, fragmente davon und multispezifische bindungsmoleküle
WO2022029080A1 (en) 2020-08-03 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
US20240175873A1 (en) 2021-03-23 2024-05-30 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
EP4314041A1 (de) 2021-03-30 2024-02-07 Aavnergene Inc. Modifizierter plasmagerinnungsfaktor viii und verfahren zu dessen verwendung
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022214681A1 (en) 2021-04-09 2022-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
AU2022267891A1 (en) 2021-04-27 2023-11-09 Novartis Ag Viral vector production system
EP4348260A2 (de) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitoren und deren therapeutische verwendung
JP2024527252A (ja) 2021-06-14 2024-07-24 武田薬品工業株式会社 発現の増加した組み換えｆｖｉｉｉバリアントをコードするウイルスベクターを用いた、血友病ａの遺伝子療法
EP4370148A1 (de) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp-komplex-spezifische inhibitoren von tgf-beta1 und verwendungen davon
EP4419117A1 (de) 2021-10-22 2024-08-28 Sana Biotechnology, Inc. Verfahren zur züchtung allogener t-zellen mit einem transgen in einem tcr-lokus sowie zugehörige zusammensetzungen und verfahren
EP4472740A1 (de) 2022-01-31 2024-12-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 als biomarker und biotarget bei t-zell-lymphomen
EP4479143A1 (de) 2022-02-18 2024-12-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Verwendung von tcr-defizienten car-tregs in kombination mit monoklonalen anti-tcr-komplex-antikörpern zur induzierung von dauerhafter toleranz
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
JP2025514669A (ja) 2022-04-11 2025-05-09 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍の診断及び処置のための方法
WO2023198874A1 (en) 2022-04-15 2023-10-19 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of t cell-lymphomas
EP4514846A1 (de) 2022-04-26 2025-03-05 Novartis AG Gegen il-13 und il-18 gerichtete multispezifische antikörper
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
KR20250009975A (ko) 2022-05-12 2025-01-20 아브너진 인코포레이티드 재조합 파르보바이러스 생산을 위한 조성물 및 방법
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
WO2024003310A1 (en) 2022-06-30 2024-01-04 Institut National de la Santé et de la Recherche Médicale Methods for the diagnosis and treatment of acute lymphoblastic leukemia
EP4558128A1 (de) 2022-07-21 2025-05-28 Institut National de la Santé et de la Recherche Médicale Mit einem erv syncitin funktionalisierte extrazelluläre vesikel und verwendungen davon zur frachtabgabe
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
JP2025528459A (ja) 2022-08-31 2025-08-28 アンスティテュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル（インセルム） より効率的なｃａｒ－ｔ細胞を生成する方法
WO2024050450A1 (en) 2022-08-31 2024-03-07 Gigamune, Inc. Engineered enveloped vectors and methods of use thereof
EP4583905A1 (de) 2022-09-06 2025-07-16 Institut National de la Santé et de la Recherche Médicale Neuartige car-t-doppelspaltzellen zur behandlung von cd38-positiven hämatologischen malignomen
JP2025531220A (ja) 2022-09-15 2025-09-19 ノバルティス アーゲー キメラ抗原受容体療法を使用した自己免疫障害の治療
EP4602372A1 (de) 2022-10-12 2025-08-20 Institut National de la Santé et de la Recherche Médicale Cd81 als biomarker und biotarget bei t-zell-malignitäten
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
JP2026507882A (ja) 2023-03-07 2026-03-06 スカラー ロック インコーポレイテッド 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用
WO2024209036A1 (en) 2023-04-07 2024-10-10 Institut National de la Santé et de la Recherche Médicale Generating highly pure glutamatergic neuronal populations using the pro-neural factor ascl1
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
WO2025008774A1 (en) 2023-07-05 2025-01-09 Takeda Pharmaceutical Company Limited Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2025017186A1 (en) 2023-07-20 2025-01-23 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with a tethering system for cargo delivery
WO2025048716A1 (en) 2023-08-25 2025-03-06 Axcynsis Therapeutics Pte. Ltd. Anti-alpp/alppl2 antibodies, antibody-drug conjugates, and uses thereof
TW202528337A (zh) 2023-09-15 2025-07-16 愛爾蘭商普羅希那平台科技有限公司 包括細胞穿透藥劑之方法、組合物、及套組
WO2025059515A2 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Cell penetrating agents and uses thereof
AR133829A1 (es) 2023-09-15 2025-11-05 Othair Prothena Ltd Agentes penetrantes de células y usos de los mismos
TW202530253A (zh) 2023-09-15 2025-08-01 愛爾蘭商普羅希那生物科學有限公司 抗ｔｄｐ－４３抗體及其用途
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025125363A1 (en) 2023-12-11 2025-06-19 Institut National de la Santé et de la Recherche Médicale Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
WO2025247922A1 (en) 2024-05-28 2025-12-04 Institut National de la Santé et de la Recherche Médicale Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating sepsis capillary leak syndrome
WO2025257397A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Live attenuated bordetella vaccines capable of producing and secreting heterologous antigens
WO2026002973A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Host immune cells engineered to overexpress a foxk1 polypeptide
WO2026035486A2 (en) 2024-08-05 2026-02-12 University Of Rochester G protein-coupled receptor (gpcr) agonists and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US5464774A (en) * 1984-03-05 1995-11-07 The Salk Institute For Biological Studies Bovine basic fibroblast growth factor
US5276268A (en) * 1986-08-23 1994-01-04 Hoechst Aktiengesellschaft Phosphinothricin-resistance gene, and its use
US5270171A (en) * 1987-03-06 1993-12-14 Boris Cercek Cancer-associated SCM-recognition factor, preparation and method of use
US5244797B1 (en) * 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5795737A (en) * 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9504446D0 (en) * 1995-03-06 1995-04-26 Medical Res Council Improvements in or relating to gene expression
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods

Also Published As

Publication number Publication date
AU737122B2 (en) 2001-08-09
KR20000048511A (ko) 2000-07-25
JP2001503252A (ja) 2001-03-13
US6114148C1 (en) 2012-05-01
EP0929564A1 (de) 1999-07-21
MX9902661A (en) 1999-12-31
DK0929564T3 (da) 2008-07-14
CA2265976C (en) 2009-04-21
PL192104B1 (pl) 2006-08-31
EP0929564B1 (de) 2008-03-19
KR100490321B1 (ko) 2005-05-17
BR9712077A (pt) 2003-04-29
RU2233329C2 (ru) 2004-07-27
PL191300B1 (pl) 2006-04-28
ES2304791T3 (es) 2008-10-16
CN1237977A (zh) 1999-12-08
CA2265976A1 (en) 1998-03-26
DE69738586T2 (de) 2009-05-07
WO1998012207A1 (en) 1998-03-26
DE69738586D1 (de) 2008-04-30
PL332431A1 (en) 1999-09-13
HUP9904239A2 (hu) 2000-04-28
HUP9904239A3 (en) 2001-06-28
MX259447B (en) 2008-08-08
US6114148A (en) 2000-09-05
CN1307195C (zh) 2007-03-28
CZ96899A3 (cs) 1999-09-15
EP0929564A4 (de) 2002-05-22
TR199900624T2 (xx) 1999-07-21
AU4355697A (en) 1998-04-14

Similar Documents

Publication Publication Date Title
ATE389666T1 (de) Hohe expressionsrate von proteinen
DE69635452D1 (de) Hohe expressionsrate des grün-fluoreszierenden proteins
DK0781329T4 (da) Overekspression af pattedyr- og virale proteiner
DE69131580D1 (de) GDF-1 und UOG1 Proteine
EP0653940A4 (de) Glialmitogene faktoren, ihre herstellung und verwendung.
SI1346034T1 (sl) POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA
NO902082D0 (no) Fibronektinbindende protein samt fremstilling derav.
NZ503850A (en) April - a novel protein with growth effects
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
UA84666C2 (ru) ВЫДеЛЕНнЫЙ ПОЛИНУКЛЕОТИД, КОДИРУЮЩИЙ СЛИТОЙ ПРОТЕИН С ПЕСТИЦИДНОЙ АКТИВНОСТЬЮ, И ТРАНСГЕННАЯ КЛЕТКА-ХОЗЯИН
BR9912455A (pt) ácidos nucléicos codificadores de proteìnas envolvidas em transdução sensória
NO882380D0 (no) Fibfonektin-bindende protein, samt fremstilling derav.
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
ATE316138T1 (de) Rekombinante expression von s-layer-proteinen
DE69415548D1 (de) Haemoregulatorische penta-oder hexapeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0929564

Country of ref document: EP

REN Ceased due to non-payment of the annual fee